Total
0
Shares
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Optimi Health (OPTI) finalizes planned build-out of mushroom production and research facility
  • Awards contracts for interior finishing and technology installation
  • Optimi utilized the winter season to assess construction progress and to finalize a shortlist of contractors best suited for the critical interior layout
  • Optimi has also developed a comprehensive security plan and assigned responsibility for 24/7 management to its chief of security
  • Optimi Health Corp. (OPTI) is down 1.37 per cent and is trading at C$0.72 at 11:39 am ET

Optimi Health Corp. (OPTI) is pleased to offer an activity update at its 20,000 sq. ft. production and research facility in Princeton, British Columbia.

Optimi is advancing rapidly to the final build-out of its two adjacent 10,000 square foot facilities which began construction in August of 2020.

With the return of milder weather, final touches to exterior services, perimeter, and access controls are well underway.

Optimi utilized the winter season to assess construction progress and to finalize a shortlist of contractors best suited for the critical interior layout.

The entire process from engineering to tender process is now complete with all tenders graded through a fair percentile grading process including reference checks.

Agricultural production will be enhanced through the professional installation of an advanced Argus control system that provides software and hardware features.

Such features are secured local and remote connections, multiple user profiles, real-time monitoring and alarming of all critical environmental and system parameters, data recording, graphing, logging, exporting, and data import for climate simulation, in a user-friendly, scalable control environment specifically designed for horticulture.

In addition, and in accordance with Health Canada protocols, the facility will include a Region III, Level 8 product vault with a projected capacity to initially secure a licensed 50kg of Psilocybin with the ability, subject to future licensing, to easily scale up to a maximum allowable level 8 capacity of 1,250kg.

Optimi, in accordance with the respective physical security directives, has developed a comprehensive security plan and assigned responsibility for 24/7 management to its chief of security.

This includes facility-wide personnel verification and tracking, intrusion or emergency notifications, CCTV monitoring, and video archive of all secure areas, and further includes active response coordination with a local emergency, fire, and police services located nearby.

City of Princeton, Director of Economic Development, Mr. Gary Schatz notes,

“I am excited to welcome Optimi Health into the Town of Princeton Industrial Park.”

“In my opinion, they are doing an excellent job introducing this alternative business venture into our community and we are pleased to have them as a member of our business community,” added Princeton.

Optimi Health COO and Director, Bryan Safarik comments,

“Activities are moving ahead rapidly, and every day brings us another step closer to moving in and getting to work.”

“…We are committed to a plan of action designed to deliver a simple outcome; the very finest Canadian made and naturally optimized mushroom products available,” added Safarik.

Optimi is developing a sophisticated mushroom brand that focuses on the health and wellness markets.

Optimi Health Corp. (OPTI) is down 1.37 per cent and is trading at C$0.72 at 11:39 am ET.

More From The Market Herald

" Marvel Biosciences (TSXV:MRVL) developing novel non-hallucinogenic neuroplastic promoting compounds

Marvel Biosciences (MRVL) has launched a program to identify and develop agents that promote neuroplasticity without the risks or side effects of psychedelics.

" Entheon Biomedical (CSE:ENBI) provides corporate update

Entheon Biomedical (ENBI) is pleased to provide an update on its operations and progress on its strategic initiatives.
Small Pharma - CEO, Peter Rands.

" Small Pharma (TSXV:DMT) granted European patent

Small Pharma (DMT) has been granted a European patent, strengthening its ketamine-based patent portfolio.

" Levitee Labs (CSE:LVT) enters into credit facility for up to $12 Million

Levitee Labs Inc. (LVT) has entered into a financing agreement for up to $12 million to fund further business expansion.